IP Library Granted Patent US 12,012,626
Granted Patent B2
US 12,012,626 · App. 17/546,758 · Granted Jun 18, 2024

Production of steviol glycosides through whole cell biotransformation of steviol glycoside intermediates

Inventors: Ajikumar Parayil Kumaran (Watertown, MA); Christine Nicole S. Santos (Newton, MA); Jason Eric Donald (Lexington, MA); Mary Elizabeth Fowler (Somerville, MA); Ryan N. Philippe (Somerville, MA); Christopher Scott Frei (Weymouth, MA); Aaron Love (Boston, MA)
Assignee: Manus Bio Inc.
C12P19/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,012,626
App. No.
17/546,758
Granted
Jun 18, 2024
Kind
B2
Abstract

In various aspects and embodiments, the invention provides microbial cells and methods for producing advanced glycosylation products from lower glycosylated intermediates. The microbial cell expresses one or more UDP-dependent glycosyl transferase enzymes in the cytoplasm, for glycosylation of the intermediates. When incubating the microbial strain with a plant extract or fraction thereof comprising the intermediates, these glycosylated intermediates are available for further glycosylation by the cell, and the advanced glycosylation products can be recovered from the media and/or microbial cells.

Claims (20)

1. A method for producing a glycosylated product from glycoside intermediates, comprising:

providing a bacterial cell expressing one or more UDP-dependent glycosyl transferase enzymes (UGT enzymes) intracellularly wherein the UGT enzymes glycosylate steviol glycoside substrates, wherein the bacterial cell has an overexpression of phosphoglucomutase (pgm) and UTP-glucose-1-phosphate uridylyltransferase; and a deletion, inactivation, or reduced expression of one or more genes encoding enzymes that consume UDP-glucose selected from a UDP-sugar hydrolase, an enzyme responsible for UDP-galactose biosynthesis from UDP-glucose, a trehalose-6-phosphate synthase, and a UDP-glucose-6-dehydrogenase,

incubating the bacterial strain with the glycoside intermediates, wherein the glycoside intermediates are steviol glycosides from stevia leaf extract, and

recovering the glycosylated product.

2. The method of claim 1 , wherein the glycosylated product comprises RebM.

3. The method of claim 1 , wherein the glycosylated product comprises RebD and/or RebI.

4. The method of claim 1 , wherein the bacterial cell has a deletion, inactivation, or reduced activity of ushA and/or one or more of galE, galT, galK, and galM.

5. The method of claim 4 , wherein galETKM genes are inactivated, deleted, or reduced in expression.

6. The method of claim 1 , wherein the bacterial cell has a deletion, inactivation, or reduced activity or expression of trehalose-6-phosphate synthase.

7. The method of claim 1 , wherein the bacterial cell has a deletion, inactivation, or reduced activity or expression of UDP-glucose 6-dehydrogenase.

8. The method of claim 1 , wherein the bacterial cell has a deletion, inactivation, or reduced activity or expression of glucose-6 phosphate isomerase.

9. The method of claim 1 , wherein the method is performed by batch fermentation, continuous fermentation, or semi-continuous fermentation.

10. The method of claim 9 , wherein the method is performed by fed batch fermentation.

11. The method of claim 10 , wherein the glycoside intermediates are incubated with the cell for about 72 hours or less.

12. The method of claim 1 , wherein the bacterial cell is selected from Escherichia spp., Bacillus spp., Rhodobacter spp., Zymomonas spp., or Pseudomonas spp.

13. The method of claim 12 , wherein the bacterial cell is a species selected from Escherichia coli, Bacillus subtilis, Rhodobacter capsulatus, Rhodobacter sphaeroides, Zymomonas mobilis , or Pseudomonas putida.

14. The method of claim 13 , wherein the bacterial cell is Escherichia coli.

15. The method of claim 1 , wherein the bacterial cell expresses a 1-3′ glycosylating UGT enzyme and a 1-2′ glycosylating enzyme.

16. The method of claim 15 , wherein the 1-3′ glycosylating UGT enzyme comprises an amino acid sequence selected from SEQ ID NO: 3, SEQ ID NO: 10, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, and derivatives thereof having at least 90% sequence identity thereto.

17. The method of claim 15 , wherein the 1-2′ glycosylating UGT enzyme comprises an amino acid sequence selected from SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, and SEQ ID NO: 11, and derivatives thereof having at least 90% sequence identity thereto.

Assignments (4)
SECURITY INTEREST Recorded Sep 8, 2025
From: MANUS BIO INC.; STO.PERU I LLC; STO.PERU II LLC; MANUS INTERMEDIATE INC.; MANUS INSCRIPTA, INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 072836/0255 →
RELEASE OF SECURITY INTEREST Recorded May 9, 2025
From: EICF AGENT LLC
To: MANUS BIO INC.
Reel/Frame 071247/0658 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2022
From: PARAYIL KUMARAN, AJIKUMAR; SANTOS, CHRISTINE NICOLE NICOLE S.; DONALD, JASON ERIC; FOWLER, MARY ELIZABETH; PHILIPPE, RYAN N.; FREI, CHRISTOPHER SCOTT; LOVE, AARON
To: MANUS BIO INC.
Reel/Frame 060770/0194 →
SECURITY AGREEMENT Recorded Apr 1, 2022
From: MANUS BIO INC.
To: EICF AGENT LLC
Reel/Frame 059568/0683 →
Continuity (3)
Continuation 16512874 · Jul 16, 2019
Provisional Application 62698617 · Jul 16, 2018
Related Publication 20220162658A1 · May 26, 2022